Safety and Side Effects of Rifampin versus Isoniazid in Children
- 2 August 2018
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 379 (5), 454-463
- https://doi.org/10.1056/nejmoa1714284
Abstract
The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment — 9 months of isoniazid — has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been shown to be safer and to have higher completion rates than 9 months of isoniazid. In this multicenter, open-label trial, we randomly assigned 844 children (M. tuberculosis infection to receive either 4 months of rifampin or 9 months of isoniazid. The primary outcome was adverse events of grade 1 to 5 that resulted in the permanent discontinuation of a trial drug. Secondary outcomes were treatment adherence, side-effect profile, and efficacy. Independent review panels whose members were unaware of trial-group assignments adjudicated all adverse events and progression to active tuberculosis. Of the children who underwent randomization, 829 were eligible for inclusion in the modified intention-to-treat analysis. A total of 360 of 422 children (85.3%) in the rifampin group completed per-protocol therapy, as compared with 311 of 407 (76.4%) in the isoniazid group (adjusted difference in the rates of treatment completion, 13.4 percentage points; 95% confidence interval [CI], 7.5 to 19.3). There were no significant between-group differences in the rates of adverse events, with fewer than 5% of the children in the combined groups with grade 1 or 2 adverse events that were deemed to be possibly related to a trial drug. Active tuberculosis, including 1 case with resistance to isoniazid, was diagnosed in 2 children in the isoniazid group during 542 person-years of follow-up, as compared with no cases in the rifampin group during 562 person-years (rate difference, −0.37 cases per 100 person-years; 95% CI, −0.88 to 0.14). Among children under the age of 18 years, treatment with 4 months of rifampin had similar rates of safety and efficacy but a better rate of adherence than 9 months of treatment with isoniazid. (Funded by the Canadian Institutes of Health Research and Conselho Nacional de Pesquisa; ClinicalTrials.gov number, NCT00170209.)Funding Information
- Canadian Institutes of Health Research (MOP-111080)
- Conselho Nacional de Pesquisa (470344/2011-3)
This publication has 22 references indexed in Scilit:
- Three Months of Rifapentine and Isoniazid for Latent Tuberculosis InfectionThe New England Journal of Medicine, 2011
- Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization RecommendationsAntimicrobial Agents and Chemotherapy, 2011
- New Regimens to Prevent Tuberculosis in Adults with HIV InfectionThe New England Journal of Medicine, 2011
- Adverse Events with 4 Months of Rifampin Therapy or 9 Months of Isoniazid Therapy for Latent Tuberculosis InfectionAnnals of Internal Medicine, 2008
- The Effectiveness of a 9-Month Regimen of Isoniazid Alone versus 3- and 4-Month Regimens of Isoniazid plus Rifampin for Treatment of Latent Tuberculosis Infection in Children: Results of an 11-Year Randomized StudyClinical Infectious Diseases, 2007
- Enhancement of Treatment Completion for Latent Tuberculosis Infection With 4 Months of RifampinSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2006
- Weekly Rifapentine/Isoniazid or Daily Rifampin/Pyrazinamide for Latent Tuberculosis in Household ContactsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Treatment Completion and Costs of a Randomized Trial of Rifampin for 4 Months versus Isoniazid for 9 MonthsAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- A Double-blind Placebo-controlled Clinical Trial of Three Antituberculosis Chemoprophylaxis Regimens in Patients with Silicosis in Hong KongAmerican Review of Respiratory Disease, 1992